A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer

The purpose of this study is to determine whether treatment with ZACTIMA (vandetanib) in combination with FOLFOX is more effective than FOLFOX alone for colorectal cancer in patients who have failed therapy with an irinotecan and fluoropyrimidine containing regimen.

本研究旨在明确，对于既往接受含伊立替康（irinotecan）与氟嘧啶类药物的治疗方案且治疗失败的结直肠癌患者，采用ZACTIMA（凡德他尼，vandetanib）联合FOLFOX方案的治疗效果是否优于单用FOLFOX方案。